The m6A Proteostatic Rheostat: A Sequestration Model for the Transition from Healthy Aging to Alzheimer’s Disease
Adaptive Hypermethylation vs. Pathological Collapse
Recent data on human brain epitranscriptomics is forcing us to rethink the assumption that m6A levels simply decline as we get older. While cognitively healthy aging is actually marked by an increase in m6A sites within the 3'UTRs of synaptic genes in the DLPFC [https://doi.org/10.1101/2025.05.02.651974], this apparent safety net disappears in Alzheimer’s Disease (AD). Specifically, AD-related hypomethylation seems to hit the ubiquitin-mediated proteolysis pathway hardest [https://doi.org/10.1101/2025.05.02.651974], which suggests the brain fails to keep the m6A "tag" on its protein-clearing machinery. When you consider that METTL3 catalytic activity is necessary to keep Tardbp (TDP-43) transcripts stable and prevent neurons from dying [https://pmc.ncbi.nlm.nih.gov/articles/PMC11216409/], m6A starts to look like a major rheostat for neuronal survival.
The "m6A Dilution" and Resource Sequestration Model
I’d argue that healthy neuronal aging is a state of "m6A hyper-compensation," where the brain ramps up METTL3/14 stoichiometry to buffer against proteostatic stress. The shift into neurodegeneration likely happens when this buffer fails because METTL3 gets pulled away by non-coding or aberrant transcripts. This essentially causes a "stoichiometric dilution" of m6A on the mRNAs that are actually vital for synapses and proteostasis.
In this model, the m6A increase we see in healthy aging isn't a sign of trouble, but a protective response to stabilize the transcripts that manage protein folding and degradation. In AD, however, the appearance of pathological RNA—things like misprocessed introns or repetitive elements—acts as a "molecular sponge" for the METTL3/14 complex. This drops the effective concentration of the writer complex available for its usual targets, like Tardbp and ubiquitin genes. Once m6A occupancy on those genes falls below a certain functional threshold, they lose the stability or translational efficiency they need to keep the cell running.
Mechanistic Reasoning: Beyond Simple Expression Levels
We can't just look at total METTL3 protein levels and call it a day. If METTL3 expression stays the same but its targets change, the distribution of m6A becomes the real driver of the disease.
- Stoichiometric Thresholds: We know from mouse models that dropping m6A stoichiometry on Tardbp from ~70% down to ~40% is enough to kick-start neurodegeneration [https://pmc.ncbi.nlm.nih.gov/articles/PMC11216409/]. It's likely that in AD, even if METTL3 levels look normal, the "writer-to-transcript" ratio is ruined because an expanded pool of "bait" RNAs is hogging the machinery.
- Epigenetic Synergy: This epitranscriptomic collapse probably feeds into other issues, like the H3K9me3-mediated impairment of the mitochondrial UPR [https://doi.org/10.1101/2024.06.17.599276]. A neuron facing mitochondrial failure needs more proteostatic support, but it's exactly then that the m6A-mediated stabilization of the ubiquitin-proteasome system (UPS) fails, creating a lethal feedback loop.
Falsifiability and Testing
To see if this holds up, we need a few things:
- Cross-sectional m6A-CLIP-seq: We need to quantify the ratio of m6A-tagged canonical mRNAs versus non-coding/aberrant transcripts in healthy aged brains versus AD brains. I’d expect to find a major "sink" of m6A on non-coding species in the AD samples.
- Synthetic Sequestration: If we overexpress m6A-"decoy" RNA oligonucleotides in healthy primary neurons, it should mimic the AD-like hypomethylation of ubiquitin genes and trigger a proteostatic collapse, even if METTL3 levels are kept at wild-type levels.
- SAM Availability: We should measure S-adenosylmethionine (SAM) levels in situ. It's possible that metabolic exhaustion limits METTL3 activity during the slide from healthy aging to AD, making the stoichiometric dilution even worse.